Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Blood

• Publication date

  2000-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V95.5.1663.005K44_1663_1670PMID 10688822
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Involvement of wiskott-aldrich syndrome protein in B-cell cytoplasmic tyrosine kinase pathway.

  1999cited by this paper
• Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice.

  1999cited by this paper
• The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization.

  1999cited by this paper
• Phosphoinositide 3‐kinase and integrin signalling are involved in activation of Bruton tyrosine kinase in thrombin‐stimulated platelets

  1999cited by this paper
• Platelet surface collagen receptor polymorphisms: variable receptor expression and thrombotic/hemorrhagic risk.

  1999cited by this paper
• Tyrosine Phosphorylation of SLP-76 Is Downstream of Syk following Stimulation of the Collagen Receptor in Platelets*

  1999cited by this paper
• Collagen induces tyrosine phosphorylation of Wiskott-Aldrich syndrome protein in human platelets.

  1998cited by this paper
• Involvement of Bruton's Tyrosine Kinase in FcεRI-dependent Mast Cell Degranulation and Cytokine Production

  1998cited by this paper
• Physical and Functional Association of the Src Family Kinases Fyn and Lyn with the Collagen Receptor Glycoprotein VI-Fc Receptor γ Chain Complex on Human Platelets

  1998cited by this paper
• Phosphatidylinositol‐3,4,5‐trisphosphate (PtdIns‐3,4,5‐P3)/Tec kinase‐dependent calcium signaling pathway: a target for SHIP‐mediated inhibitory signals

  1998cited by this paper
• Phosphatidylinositol 3,4,5-Trisphosphate-dependent Stimulation of Phospholipase C-γ2 Is an Early Key Event in FcγRIIA-mediated Activation of Human Platelets*

  1998cited by this paper
• A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.

  1998cited by this paper
• Tec is involved in G protein-coupled receptor- and integrin-mediated signalings in human blood platelets

  1998cited by this paper
• Btk function in B cell development and response.

  1998cited by this paper
• Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B‐cell receptor activation

  1998cited by this paper
• Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation.

  1998cited by this paper
• Collagen receptor signalling in platelets: extending the role of the ITAM.

  1998cited by this paper
• Tyrosine phosphorylation of the Wiskott‐Aldrich Syndrome protein by Lyn and Btk is regulated by CDC42

  1998cited by this paper
• The Wiskott-Aldrich syndrome

  1998cited by this paper
• Integrin-dependent tyrosine phoshorylation and cytoskeletal translocation of Tec in thrombin-activated platelets.

  1997cited by this paper
• Platelet Adhesion to Collagen: an Update

  1997cited by this paper
• Direct stimulation of Bruton's tyrosine kinase by G(q)-protein alpha-subunit.

  1997cited by this paper
• The identification of Bruton's tyrosine kinase and Wiskott-Aldrich syndrome protein associated proteins and signalling pathways.

  1997cited by this paper
• Btk dosage determines sensitivity to B cell antigen receptor cross-linking.

  1997cited by this paper
• Platelet signal transduction defect with Gα subunit dysfunction and diminished Gαq in a patient with abnormal platelet responses

  1997cited by this paper
• A Novel Association of Fc Receptor γ-Chain with Glycoprotein VI and Their Co-expression as a Collagen Receptor in Human Platelets*

  1997cited by this paper
• Impaired Ca2+ mobilization by X‐linked agammaglobulinaemia (XLA) B cells in response to ligation of the B cell receptor (BCR)

  1997cited by this paper
• Defective platelet activation in Gαq-deficient mice

  1997cited by this paper
• Direct stimulation of Bruton's tyrosine kinase by Gq-protein α-subunit

  1997cited by this paper
• Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain.

  1997cited by this paper
• Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases.

  1997cited by this paper
• Defective platelet activation in G alpha(q)-deficient mice.

  1997cited by this paper
• Platelet Activation and Signal Transduction by Convulxin, a C-type Lectin from Crotalus durissus terrificus (Tropical Rattlesnake) Venom via the p62/GPVI Collagen Receptor*

  1997cited by this paper
• Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors.

  1997cited by this paper
• The Fc receptor γ‐chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen

  1997cited by this paper
• Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses.

  1997cited by this paper
• Phosphatidylinositol 3-kinase-γ activates Bruton’s tyrosine kinase in concert with Src family kinases

  1997cited by this paper
• Platelet Receptors for Collagen

  1997cited by this paper
• Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor γ‐chain

  1997cited by this paper
• Effects of recombinant human megakaryocyte growth and development factor on platelet activation.

  1996cited by this paper
• A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2

  1996cited by this paper
• Activation of BTK by a Phosphorylation Mechanism Initiated by SRC Family Kinases

  1996cited by this paper
• Phosphoinositide 3-kinase activation and platelet function.

  1996cited by this paper
• Immunodeficiency in protein kinase cbeta-deficient mice.

  1996cited by this paper
• Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation.

  1996cited by this paper
• p120c-cbl is present in human blood platelets and is differentially involved in signaling by thrombopoietin and thrombin.

  1996cited by this paper
• Identification of Regions of the Wiskott-Aldrich Syndrome Protein Responsible for Association with Selected Src Homology 3 Domains*

  1996cited by this paper
• Evidence that the Wiskott-Aldrich syndrome protein may be involved in lymphoid cell signaling pathways.

  1996cited by this paper
• Immunodeficiency in Protein Kinase Cβ-Deficient Mice

  1996cited by this paper
• Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets.

  1996cited by this paper
• Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists.

  1996cited by this paper
• Activation of Tsk and Btk tyrosine kinases by G protein beta gamma subunits.

  1995cited by this paper
• Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets.

  1995cited by this paper
• Thrombopoietin, c‐Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists‐induced aggregation in platelets in vitro

  1995cited by this paper
• Src family protein tyrosine kinases induce autoactivation of Bruton's tyrosine kinase

  1995cited by this paper
• Modulation of Platelet Activation In Vitro by Thrombopoietin

  1995cited by this paper
• Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin.

  1995cited by this paper
• Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation

  1995cited by this paper
• The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C.

  1994cited by this paper
• Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase.

  1994cited by this paper
• Molecular mechanisms of platelet activation.

  1989cited by this paper

• Involvement of Btk in Cardiovascular Disease and Its Therapeutic Targeting.

  2026cites this paper
• Evaluating rilzabrutinib in the treatment of immune thrombocytopenia

  2025cites this paper
• Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice

  2024cites this paper
• Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib

  2022cites this paper
• Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease

  2022cites this paper
• Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions

  2022cites this paper
• Design, synthesis and biological evaluation of novel pyrazolo-pyrimidin-amines as potent and selective BTK inhibitors.

  2022cites this paper
• How I treat and prevent venous thrombotic complications in patients with lymphoma.

  2021cites this paper
• Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors

  2021cites this paper
• Bruton’s Tyrosine Kinase (BTK)-Inhibitors in Cancer Therapeutics

  2021cites this paper
• Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects

  2021cites this paper
• Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease

  2021influential citation
• Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton’s Tyrosine Kinase

  2021cites this paper
• Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia

  2021influential citation
• Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time

  2021cites this paper
• Bruton tyrosine kinase in immunodeficiency and in B-cell malignancy

  2020cites this paper
• Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction

  2020cites this paper
• Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

  2020cites this paper
• Signal Transduction Pathways in Chronic Lymphocytic Leukemia

  2019cites this paper
• Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib

  2019cites this paper
• Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.

  2019cites this paper
• DDDT_A_211907 4225..4238

  2019cites this paper
• Management of adverse effects/toxicity of ibrutinib.

  2019cites this paper
• From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks

  2019cites this paper
• Ibrutinib for the treatment of chronic lymphocytic leukemia

  2019cites this paper
• Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?

  2019influential citation
• Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.

  2019cites this paper
• Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

  2019cites this paper
• Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib

  2019cites this paper
• Platelet Signal Transduction

  2019cites this paper
• Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?

  2019cites this paper
• Role of Bruton’s tyrosine kinase in B cells and malignancies

  2018cites this paper
• Monitoring and Management of Toxicities of Novel B Cell Signaling Agents

  2018cites this paper
• Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans.

  2018cites this paper
• Modification of immunological features in human platelets during sepsis

  2018cites this paper
• The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen‐induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)

  2018cites this paper
• Receptor-guided 3D-QSAR studies, molecular dynamics simulation and free energy calculations of Btk kinase inhibitors

  2017cites this paper
• The safety of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia

  2017cites this paper
• Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis.

  2017cites this paper
• The role of scavenger receptors in oxidised low-density lipoprotein induced platelet hyperactivity

  2016cites this paper
• The importance of bruton tyrosine kinase (BTK) and targeted therapies

  2016cites this paper
• Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses

  2016cites this paper
• Progress in Chronic Lymphocytic Leukemia with Targeted Therapy.

  2016cites this paper
• The role of platelets in sepsis

  2015cites this paper
• Bruton’s Tyrosine Kinase (BTK) Beyond B Lymphocytes: A Protein Kinase with Relevance in Innate Immunity

  2015cites this paper
• Targets for Ibrutinib Beyond B Cell Malignancies

  2015cites this paper
• Distinct Pathways Regulate Syk Protein Activation Downstream of Immune Tyrosine Activation Motif (ITAM) and hemITAM Receptors in Platelets*

  2015cites this paper
• Ibrutinib Inhibits Platelet Integrin &agr;IIb&bgr;3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen

  2015influential citation
• Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

  2015cites this paper
• Platelet Immunoreceptor Tyrosine-Based Activation Motif Signaling in Hemostasis Platelet Immunoreceptor Tyrosine-Based Activation Motif (ITAM) Signaling and Vascular Integrity on

  2014cites this paper
• Platelet ITAM Signaling and Vascular Integrity

  2014cites this paper
• BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future

  2014cites this paper
• Platelet Immunoreceptor Tyrosine-Based Activation Motif Signaling in Hemostasis and Thrombosis

  2014cites this paper
• Platelet Immunoreceptor Tyrosine-Based Activation Motif Signaling in Hemostasis Platelet Immunoreceptor Tyrosine-Based Activation Motif (ITAM) Signaling and Vascular Integrity on

  2014cites this paper
• Platelet Immunoreceptor Tyrosine-Based Activation Motif Signaling in Hemostasis Platelet Immunoreceptor Tyrosine-Based Activation Motif (ITAM) Signaling and Vascular Integrity on

  2014cites this paper
• Platelet Immunoreceptor Tyrosine-Based Activation Motif Signaling in Hemostasis Platelet Immunoreceptor Tyrosine-Based Activation Motif (ITAM) Signaling and Vascular Integrity on

  2014cites this paper
• Platelet Immunoreceptor Tyrosine-Based Activation Motif Signaling in Hemostasis Platelet Immunoreceptor Tyrosine-Based Activation Motif (ITAM) Signaling and Vascular Integrity on

  2014cites this paper
• Platelet Immunoreceptor Tyrosine-Based Activation Motif (ITAM) Signaling and Vascular Integrity

  2014cites this paper
• Platelet Immunoreceptor Tyrosine-Based Activation Motif Signaling in Hemostasis Platelet Immunoreceptor Tyrosine-Based Activation Motif (ITAM) Signaling and Vascular Integrity on

  2014cites this paper
• Receptor-Induced Signaling and γ and Tec Kinase during Fc Dual Functions of Bruton's Tyrosine Kinase

  2013influential citation
• RIIa on the platelet plasma membrane γ receptor Fc Physical proximity and functional interplay of PECAM-1 with the Fc

  2013cites this paper
• Wiskott-Aldrich Syndrome Protein (WASp) Controls the Delivery of Platelet Transforming Growth Factor-β1*

  2013cites this paper
• signaling and GPIb-dependent thrombus formation in vivo Bruton tyrosine kinase is essential for botrocetin/VWF-induced

  2013cites this paper
• Antiplatelet Agents

  2012cites this paper
• Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy

  2012cites this paper
• Intracellular signaling as a potential target for antiplatelet therapy.

  2012cites this paper
• Characterisation of cyclic adenosine monophosphate/protein kinase A signalling networks in blood platelets

  2012cites this paper
• LXR as a novel antithrombotic target.

  2011cites this paper
• Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity

  2010cites this paper
• The Tec Family Kinase Itk Exists as a Folded Monomer in Vivo*

  2009cites this paper
• Primary B cell immunodeficiencies: comparisons and contrasts.

  2009cites this paper
• Immunodeficiencies: Comparisons and Contrasts

  2009cites this paper
• β1 integrin regulation

  2009cites this paper
• Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.

  2009cites this paper
• Molecular and biological aspects of primary immunodeficiency

  2009cites this paper
• Phylogeny of Tec family kinases identification of a premetazoan origin of Btk, Bmx, Itk, Tec, Txk, and the Btk regulator SH3BP5.

  2008influential citation
• Clinical Potential of Targeting Bruton's Tyrosine Kinase

  2008cites this paper
• Bruton's tyrosine kinase as a drug discovery target.

  2008cites this paper
• Dual Functions of Bruton’s Tyrosine Kinase and Tec Kinase during Fcγ Receptor-Induced Signaling and Phagocytosis1

  2008influential citation
• Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis.

  2008cites this paper
• Bruton's tyrosine kinase as a new therapeutic target.

  2007cites this paper
• Tec Kinase Itk Forms Membrane Clusters Specifically in the Vicinity of Recruiting Receptors*

  2006cites this paper
• Mechanisms of Disease Persistence in Chronic Myelogenous Leukemia (CML)

  2006cites this paper
• Étude des réponses phagocytaires et chimiotactiques du neutrophile humain dans des modèles in vitro

  2006cites this paper
• Bruton’s tyrosine kinase is essential for botrocetin/vWf-induced signaling and GPIb-dependent thrombus formation in vivo.

  2006cites this paper
• Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.

  2006cites this paper
• Bruton’s tyrosine kinase is essential for botrocetin/vWf-induced signaling and GPIb-dependent thrombus formation in vivo. Running title: GPIb/IX/V-mediated outside-in signaling Hemostasis, Thrombosis, & Vascular Biology

  2006cites this paper
• Genetic analysis of patients with defects in early B‐cell development

  2005cites this paper
• Platelet adhesion signalling and the regulation of thrombus formation

  2004influential citation
• CHAPTER 26 – Immunodeficiencies Caused by B-Cell Defects

  2004cites this paper
• Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK).

  2004cites this paper
• The Role of Tec Family Kinases in Myeloid Cells

  2004cites this paper
• characterized by an impaired response to GP VI stimulation null platelets α Functional phenotype of phosphoinositide 3-kinase p85

  2003cites this paper
• Immunodeficiency disorders.

  2003cites this paper
• Molecular biology of Brouton´s tyrosine kinase

  2003cites this paper
• Functional phenotype of phosphoinositide 3-kinase p85alpha-null platelets characterized by an impaired response to GP VI stimulation.

  2003cites this paper
• Tec regulates platelet activation by GPVI in the absence of Btk.

  2003cites this paper
• Plasma membrane Ca2+-ATPase isoform 4b is phosphorylated on tyrosine 1176 in activated human platelets

  2003influential citation
• The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.

  2003cites this paper
• The Anti-leukemic Bruto n's Tyrosine Kinase Inhibitor α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) Propenamide (LFM-A13) Prevents Fatal Thromboembolism

  2003cites this paper